Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | PIR | O00625 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24790477 | 0.92 | LMNA (0.44) | LMNAARCA9CYP1A2CYP3A4 | |
| SCHEMBL19067483 | 0.91 | LMNA (0.39) | LMNAARCA9CYP1A2CYP3A4 | |
| SCHEMBL27032146 | 0.87 | LMNA (0.44) | LMNAARCA9CYP1A2CYP3A4 | |
| SCHEMBL8250599 | 0.87 | LMNA (0.44) | LMNAARCA9CYP1A2CYP3A4 | |
| SCHEMBL18495737 | 0.87 | LMNA (0.44) | LMNAARCA9CYP1A2CYP3A4 | |
| SCHEMBL9863407 | 0.87 | PLA2G2C (0.44) | LMNAALDH1A1SMN1; SMN2CNR2 | |
| SCHEMBL25967516 | 0.87 | PLA2G2C (0.44) | LMNAALDH1A1SMN1; SMN2CNR2 | |
| SCHEMBL1105205 | 0.87 | ALDH1A1 (0.44) | LMNAARCA9CYP1A2CYP3A4 | |
| SCHEMBL9149483 | 0.86 | LMNA (0.43) | LMNAARCA9CYP1A2CYP3A4 | |
| SCHEMBL30831419 | 0.85 | ALDH1A1 (0.49) | LMNACA9CYP1A2CYP3A4BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4464703-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4245756-B1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-4245756-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-8158616-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2288610-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | IKZF2, IKZF1, IKZF3 | LMNA 2695/4885AR 3211/4885CA9 4452/4885 |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | LMNA 2695/4885AR 3211/4885CA9 4452/4885 |
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | LMNA 4853/4885AR 1917/4885CA9 1784/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | LMNA 4853/4885AR 1917/4885CA9 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.